Clinical trial
A Study Evaluating the Efficacy and Safety of the LentiGlobin® BB305 Drug…
NCT02906202 · Genetix Biotherapeutics Inc., Industry · Completed
Key facts
| NCT number | NCT02906202 |
|---|---|
| Title | A Study Evaluating the Efficacy and Safety of the LentiGlobin® BB305 Drug Product in Participants With Transfusion-Dependent β-Thalassemia, Who do Not Have a β0/β0 Genotype |
| Official title | A Phase 3 Single Arm Study Evaluating the Efficacy and Safety of Gene Therapy in Subjects With Transfusion-dependent β-Thalassemia, Who do Not Have a β0/β0 Genotype, by Transplantation of Autologous CD34+ Stem Cells Transduced Ex Vivo With a Lentiviral βA-T87Q-Globin Vector in Subjects ≤50 Years of… |
| Lead sponsor | Genetix Biotherapeutics Inc., Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Beta-Thalassemia |
| Intervention type | Genetic |
| Interventions | LentiGlobin BB305 Drug Product |
| Enrollment | 24 |
| Start date | Aug 8, 2016 |
| Primary completion | Mar 31, 2022 |
| Completion | Mar 31, 2022 |
| First posted | Sep 20, 2016 |
| Last update posted | Jun 18, 2023 |
| Countries | France, Germany, Italy, Thailand, United Kingdom, United States |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: